{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:43:07Z","timestamp":1790800987478,"version":"4.1.0"},"reference-count":236,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T00:00:00Z","timestamp":1730592000000},"content-version":"am","delay-in-days":338,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["7R01AI150381\u201302"],"award-info":[{"award-number":["7R01AI150381\u201302"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007557","name":"California Institute of Regenerative Medicine","doi-asserted-by":"publisher","award":["DISC2\u201313510"],"award-info":[{"award-number":["DISC2\u201313510"]}],"id":[{"id":"10.13039\/100007557","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.clim.2023.109809","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T02:11:36Z","timestamp":1697422296000},"page":"109809","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Broadly neutralizing antibodies targeting HIV: Progress and challenges"],"prefix":"10.1016","volume":"257","author":[{"given":"Nandagopal","family":"Paneerselvam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian R.","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2023.109809_bb0010","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jim.2007.09.017","article-title":"Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning","volume":"329","author":"Tiller","year":"2008","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.clim.2023.109809_bb0015","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00002030-200201250-00012","article-title":"A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1","volume":"16","author":"Armbruster","year":"2002","journal-title":"AIDS Lond. Engl."},{"key":"10.1016\/j.clim.2023.109809_bb0020","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1097\/00002030-200210180-00006","article-title":"Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation","volume":"16","author":"Stiegler","year":"2002","journal-title":"AIDS Lond. Engl."},{"key":"10.1016\/j.clim.2023.109809_bb0025","doi-asserted-by":"crossref","first-page":"8793","DOI":"10.1128\/JVI.00598-07","article-title":"In Vivo and In Vitro Escape from Neutralizing Antibodies 2G12, 2F5, and 4E10","volume":"81","author":"Manrique","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.clim.2023.109809_bb0030","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nm1244","article-title":"Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies","volume":"11","author":"Trkola","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2023.109809_bb0035","doi-asserted-by":"crossref","first-page":"11016","DOI":"10.1128\/JVI.01340-07","article-title":"Adjunctive Passive Immunotherapy in Human Immunodeficiency Virus Type 1-Infected Individuals Treated with Antiviral Therapy during Acute and Early Infection","volume":"81","author":"Mehandru","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.clim.2023.109809_bb0040","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1084\/jem.20121977","article-title":"Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies","volume":"210","author":"Yang","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2023.109809_bb0045","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1128\/JVI.02853-13","article-title":"Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies","volume":"88","author":"deCamp","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.clim.2023.109809_bb0050","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/978-1-59745-170-3_26","article-title":"Measuring HIV neutralization in a luciferase reporter gene assay","volume":"485","author":"Montefiori","year":"2009","journal-title":"Methods Mol. Biol. Clifton NJ."},{"key":"10.1016\/j.clim.2023.109809_bb0055","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nature12744","article-title":"Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys","volume":"503","author":"Barouch","year":"2013","journal-title":"Nature."},{"key":"10.1016\/j.clim.2023.109809_bb0060","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nature12746","article-title":"Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia","volume":"503","author":"Shingai","year":"2013","journal-title":"Nature."},{"key":"10.1016\/j.clim.2023.109809_bb0065","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nature21435","article-title":"Early antibody therapy can induce long-lasting immunity to SHIV","volume":"543","author":"Nishimura","year":"2017","journal-title":"Nature."},{"key":"10.1016\/j.clim.2023.109809_bb0070","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/s41591-018-0001-2","article-title":"A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection","volume":"24","author":"Gautam","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2023.109809_bb0075","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/infdis\/jiac041","article-title":"Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention","volume":"226","author":"Mahomed","year":"2022","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.clim.2023.109809_bb0080","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","article-title":"Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition, N","volume":"384","author":"Corey","year":"2021","journal-title":"Engl. J. Med."},{"key":"10.1016\/j.clim.2023.109809_bb0085","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-042247","article-title":"Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: Study protocol for the first-in-human CAPRISA 012B phase i clinical trial","volume":"10","author":"Mahomed","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.clim.2023.109809_bb0090","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/infdis\/jiz532","article-title":"IMPAACT P1112 team, Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants","volume":"222","author":"Cunningham","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.clim.2023.109809_bb0095","doi-asserted-by":"crossref","first-page":"e667","DOI":"10.1016\/S2352-3018(19)30181-X","article-title":"Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial","volume":"6","author":"Gaudinski","year":"2019","journal-title":"Lancet HIV."},{"key":"10.1016\/j.clim.2023.109809_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0219142","article-title":"Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: a randomized, phase 1 study","volume":"14","author":"Cohen","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.clim.2023.109809_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002493","article-title":"Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults","volume":"15","author":"Gaudinski","year":"2018","journal-title":"PLoS Med."},{"key":"10.1016\/j.clim.2023.109809_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002435","article-title":"Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial","volume":"14","author":"Mayer","year":"2017","journal-title":"PLoS Med."},{"key":"10.1016\/j.clim.2023.109809_bb0115","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/cei.12692","article-title":"Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults","volume":"182","author":"Ledgerwood","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.clim.2023.109809_bb0120","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature."},{"key":"10.1016\/j.clim.2023.109809_bb0125","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad5752","article-title":"Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection","volume":"7","author":"Lynch","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.clim.2023.109809_bb0130","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nm.4268","article-title":"Antibody 10-1074 suppresses viremia in HIV-1-infected individuals","volume":"23","author":"Caskey","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2023.109809_bb0135","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1038\/s41591-021-01509-0","article-title":"Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial","volume":"27","author":"Stephenson","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2023.109809_bb0140","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/s41591-022-01815-1","article-title":"Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial","volume":"28","author":"Julg","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2023.109809_bb0145","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1016\/S2352-3018(19)30053-0","article-title":"Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"6","author":"Crowell","year":"2019","journal-title":"Lancet HIV."},{"key":"10.1016\/j.clim.2023.109809_bb0150","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25453","article-title":"Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on-going viral transcription","volume":"23","author":"Pannus","year":"2020","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.clim.2023.109809_bb0155","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1097\/QAD.0000000000002629","article-title":"No HIV-1 molecular evolution on long-term antiretroviral therapy initiated during primary HIV-1 infection","volume":"34","author":"Abdi","year":"2020","journal-title":"AIDS Lond. Engl."},{"key":"10.1016\/j.clim.2023.109809_bb0160","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/QAD.0000000000003088","article-title":"Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individuals","volume":"36","author":"Moldt","year":"2022","journal-title":"AIDS Lond. Engl."},{"key":"10.1016\/j.clim.2023.109809_bb0165","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature18929","article-title":"HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption","volume":"535","author":"Scheid","year":"2016","journal-title":"Nature."},{"key":"10.1016\/j.clim.2023.109809_bb0170","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","article-title":"Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption","volume":"375","author":"Bar","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2023.109809_bb0175","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1172\/JCI134395","article-title":"Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound","volume":"130","author":"Cale","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2023.109809_bb0180","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-34171-2","article-title":"Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity","volume":"13","author":"Ros\u00e1s-Umbert","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.clim.2023.109809_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010574","article-title":"Broad coverage of neutralization-resistant SIV strains by second-generation SIV-specific antibodies targeting the region involved in binding CD4","volume":"18","author":"Welles","year":"2022","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.clim.2023.109809_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110199","article-title":"Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys","volume":"38","author":"Pegu","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.clim.2023.109809_bb0195","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination therapy with anti-HIV-1 antibodies maintains viral suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature."},{"key":"10.1016\/j.clim.2023.109809_bb0200","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41591-018-0186-4","article-title":"Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals","volume":"24","author":"Bar-On","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2023.109809_bb0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003477","article-title":"Evidence for a Continuous Drift of the HIV-1 Species towards Higher Resistance to Neutralizing Antibodies over the Course of the Epidemic","volume":"9","author":"Bouvin-Pley","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.clim.2023.109809_bb0210","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12977-016-0304-7","article-title":"Enhanced antibody-mediated neutralization of HIV-1 variants that are resistant to fusion inhibitors","volume":"13","author":"Alam","year":"2016","journal-title":"Retrovirology."},{"key":"10.1016\/j.clim.2023.109809_bb0215","doi-asserted-by":"crossref","first-page":"6626","DOI":"10.1073\/pnas.1304288110","article-title":"Phenotypic properties of transmitted founder HIV-1","volume":"110","author":"Parrish","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.clim.2023.109809_bb0220","doi-asserted-by":"crossref","first-page":"10313","DOI":"10.1128\/JVI.01225-12","article-title":"HIV Populations Are Large and Accumulate High Genetic Diversity in a Nonlinear Fashion","volume":"87","author":"Maldarelli","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.clim.2023.109809_bb0225","doi-asserted-by":"crossref","first-page":"11273","DOI":"10.1128\/JVI.76.22.11273-11282.2002","article-title":"Human Immunodeficiency Virus Type 1 Recombination: Rate, Fidelity, and Putative Hot Spots","volume":"76","author":"Zhuang","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.clim.2023.109809_bb0230","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature01470","article-title":"Antibody neutralization and escape by HIV-1","volume":"422","author":"Wei","year":"2003","journal-title":"Nature."},{"key":"10.1016\/j.clim.2023.109809_bb0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003738","article-title":"Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes","volume":"9","author":"Wibmer","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.clim.2023.109809_bb0240","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/nm.3963","article-title":"Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies","volume":"21","author":"Bhiman","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2023.109809_bb0245","doi-asserted-by":"crossref","first-page":"312","DOI":"10.7883\/yoken.JJID.2018.336","article-title":"Higher Genetic Diversity and Viral Evolution in Key Regions of the Envelope Gene Are Associated with Broader Neutralizing Antibody Responses: a Report of Two Chronic HIV Infected Cases","volume":"72","author":"Shen","year":"2019","journal-title":"Jpn. J. Infect. Dis."},{"key":"10.1016\/j.clim.2023.109809_bb0250","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3390\/vaccines9030260","article-title":"Continuous HIV-1 Escape from Autologous Neutralization and Development of Cross-Reactive Antibody Responses Characterizes Slow Disease Progression of Children","volume":"9","author":"Dispinseri","year":"2021","journal-title":"Vaccines."},{"key":"10.1016\/j.clim.2023.109809_bb0255","article-title":"Neutralization Sensitivity of HIV-1 CRF07_BC From an Untreated Patient With a Focus on Evolution Over Time","volume":"12","author":"Wang","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.clim.2023.109809_bb0260","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.710327","article-title":"Characterizing the relationship between neutralization sensitivity and env Gene diversity during ART suppression","volume":"12","author":"Wilson","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2023.109809_bb0265","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/QAD.0000000000000106","article-title":"Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection","volume":"28","author":"Hraber","year":"2014","journal-title":"AIDS Lond. Engl."},{"key":"10.1016\/j.clim.2023.109809_bb0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005369","article-title":"Broadly neutralizing antibody responses in a large longitudinal sub-Saharan HIV primary infection cohort","volume":"12","author":"Landais","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.clim.2023.109809_bb0275","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1099\/jgv.0.001016","article-title":"Broad neutralization response in a subset of HIV-1 subtype C-infected viraemic non-progressors from southern India","volume":"99","author":"Nandagopal","year":"2018","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.clim.2023.109809_bb0280","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/nm.4187","article-title":"Determinants of HIV-1 broadly neutralizing antibody induction","volume":"22","author":"Rusert","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2023.109809_bb0285","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.cell.2015.03.004","article-title":"Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection","volume":"161","author":"Wu","year":"2015","journal-title":"Cell."},{"key":"10.1016\/j.clim.2023.109809_bb0290","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1038\/nm.2985","article-title":"Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape","volume":"18","author":"Moore","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2023.109809_bb0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1008434","article-title":"Pre-existing resistance in the latent reservoir can compromise VRC01 therapy during chronic HIV-1 infection","volume":"16","author":"Saha","year":"2020","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.clim.2023.109809_bb0300","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1473-3099(18)30647-9","article-title":"WHO\u2013UNAIDS Network for HIV Isolation Characterisation, Global and regional molecular epidemiology of HIV-1, 1990-2015: a systematic review, global survey, and trend analysis","volume":"19","author":"Hemelaar","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.clim.2023.109809_bb0305","doi-asserted-by":"crossref","first-page":"W13","DOI":"10.1097\/01.aids.0000247564.73009.bc","article-title":"Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004","volume":"20","author":"Hemelaar","year":"2006","journal-title":"AIDS Lond. Engl."},{"key":"10.1016\/j.clim.2023.109809_bb0310","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1146\/annurev-immunol-080219-023629","article-title":"Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention","volume":"38","author":"Stephenson","year":"2020","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.clim.2023.109809_bb0315","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00126-20","article-title":"Key Positions of HIV-1 Env and Signatures of Vaccine Efficacy Show Gradual Reduction of Population Founder Effects at the Clade and Regional Levels","volume":"11","author":"Han","year":"2020","journal-title":"MBio."},{"key":"10.1016\/j.clim.2023.109809_bb0320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007167","article-title":"Evolution of HIV-1 within untreated individuals and at the population scale in Uganda","volume":"14","author":"Raghwani","year":"2018","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.clim.2023.109809_bb0325","doi-asserted-by":"crossref","first-page":"12623","DOI":"10.1128\/JVI.01705-14","article-title":"Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies","volume":"88","author":"Hraber","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.clim.2023.109809_bb0330","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41586-022-04797-9","article-title":"Combination anti-HIV antibodies provide sustained virological suppression","volume":"606","author":"Sneller","year":"2022","journal-title":"Nature."},{"key":"10.1016\/j.clim.2023.109809_bb0335","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/8394","article-title":"Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy","volume":"5","author":"Finzi","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2023.109809_bb0340","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1089\/aid.2016.0171","article-title":"Quantification of Residual Germinal Center Activity and HIV-1 DNA and RNA Levels Using Fine Needle Biopsies of Lymph Nodes During Antiretroviral Therapy","volume":"33","author":"Hey-Nguyen","year":"2017","journal-title":"AIDS Res. Hum. Retrovir."},{"issue":"83","key":"10.1016\/j.clim.2023.109809_bb0345","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/QAI.0000000000002287","article-title":"Antiretroviral therapy concentrations differ in gut versus lymph node tissues and are associated with HIV viral transcription by a novel RT-ddPCR assay","volume":"1999","author":"Lee","year":"2020","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.clim.2023.109809_bb0350","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1073\/pnas.1318249111","article-title":"Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues","volume":"111","author":"Fletcher","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.clim.2023.109809_bb0355","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1084\/jem.20121932","article-title":"Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production","volume":"210","author":"Perreau","year":"2012","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2023.109809_bb0360","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01790-18","article-title":"Identification of NK Cell Subpopulations That Differentiate HIV-Infected Subject Cohorts with Diverse Levels of Virus Control","volume":"93","author":"Pohlmeyer","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.clim.2023.109809_bb0365","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000917","article-title":"Perforin Expression Directly Ex Vivo by HIV-Specific CD8+ T-Cells Is a Correlate of HIV Elite Control","volume":"6","author":"Hersperger","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.clim.2023.109809_bb0370","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature14053","article-title":"Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations","volume":"517","author":"Deng","year":"2015","journal-title":"Nature."},{"key":"10.1016\/j.clim.2023.109809_bb0375","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1089\/aid.2016.0324","article-title":"Early and Delayed Antiretroviral Therapy Results in Comparable Reductions in CD8+ T Cell Exhaustion Marker Expression","volume":"33","author":"Rutishauser","year":"2017","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.clim.2023.109809_bb0380","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.immuni.2021.08.007","article-title":"Functional impairment of HIV-specific CD8+ T cells precedes aborted spontaneous control of viremia","volume":"54","author":"Collins","year":"2021","journal-title":"Immunity."},{"key":"10.1016\/j.clim.2023.109809_bb0385","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3389\/fmicb.2019.00145","article-title":"Reduction of HIV-1 Reservoir Size and Diversity After 1 Year of cART Among Brazilian Individuals Starting Treatment During Early Stages of Acute Infection","volume":"10","author":"Leite","year":"2019","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.clim.2023.109809_bb0390","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004010","article-title":"Lack of Detectable HIV-1 Molecular Evolution during Suppressive Antiretroviral Therapy","volume":"10","author":"Kearney","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.clim.2023.109809_bb0395","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/QAD.0000000000003085","article-title":"Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy","volume":"36","author":"Mills","year":"2022","journal-title":"AIDS."},{"key":"10.1016\/j.clim.2023.109809_bb0400","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3018(22)00291-0","article-title":"Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial","volume":"10","author":"Gupta","year":"2023","journal-title":"Lancet HIV."},{"key":"10.1016\/j.clim.2023.109809_bb0410","doi-asserted-by":"crossref","first-page":"11187","DOI":"10.1073\/pnas.1019002108","article-title":"Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies","volume":"108","author":"Schaefer","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2023.109809_bb0415","doi-asserted-by":"crossref","first-page":"12501","DOI":"10.1128\/JVI.02097-15","article-title":"Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization","volume":"89","author":"Asokan","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.clim.2023.109809_bb0420","doi-asserted-by":"crossref","first-page":"2165390","DOI":"10.1080\/19420862.2023.2165390","article-title":"Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency","volume":"15","author":"Zhang","year":"2023","journal-title":"MAbs."},{"key":"10.1016\/j.clim.2023.109809_bb0425","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1126\/science.aan8630","article-title":"Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques","volume":"358","author":"Xu","year":"2017","journal-title":"Science."},{"key":"10.1016\/j.clim.2023.109809_bb0430","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/15284336.2018.1452842","article-title":"PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection","volume":"19","author":"Dhody","year":"2018","journal-title":"HIV Clin. Trials."},{"issue":"55","key":"10.1016\/j.clim.2023.109809_bb0435","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1358\/dot.2019.55.1.2895651","article-title":"Ibalizumab for the treatment of multidrug-resistant HIV-1 infection","volume":"1998","author":"Rizza","year":"2019","journal-title":"Drugs Today Barc. Spain"},{"issue":"149","key":"10.1016\/j.clim.2023.109809_bb0440","first-page":"1779","article-title":"Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion","volume":"1950","author":"Burkly","year":"1992","journal-title":"J. Immunol. Baltim. Md"},{"key":"10.1016\/j.clim.2023.109809_bb0445","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1128\/JVI.73.5.4145-4155.1999","article-title":"Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5","volume":"73","author":"Olson","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.clim.2023.109809_bb0450","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa1711460","article-title":"Phase 3 study of Ibalizumab for multidrug-resistant HIV-1","volume":"379","author":"Emu","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2023.109809_bb0455","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/1743-422X-10-120","article-title":"A monoclonal antibody against lymphocyte function-associated antigen-1 decreases HIV-1 replication by inducing the secretion of an antiviral soluble factor","volume":"10","author":"Rychert","year":"2013","journal-title":"Virol. J."},{"key":"10.1016\/j.clim.2023.109809_bb0460","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/nm.3715","article-title":"Targeting \u03b14\u03b27 integrin reduces mucosal transmission of simian immunodeficiency virus and protects gut-associated lymphoid tissue from infection","volume":"20","author":"Byrareddy","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2023.109809_bb0465","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007776","article-title":"Delayed vaginal SHIV infection in VRC01 and anti-\u03b14\u03b27 treated rhesus macaques","volume":"15","author":"Calenda","year":"2019","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.clim.2023.109809_bb0470","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/363446a0","article-title":"Naturally occurring antibodies devoid of light chains","volume":"363","author":"Hamers-Casterman","year":"1993","journal-title":"Nature."},{"key":"10.1016\/j.clim.2023.109809_bb0475","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.str.2022.03.012","article-title":"Structural basis for llama nanobody recognition and neutralization of HIV-1 at the CD4-binding site","volume":"30","author":"Zhou","year":"2022","journal-title":"Structure."},{"key":"10.1016\/j.clim.2023.109809_bb0480","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033298","article-title":"Llama antibody fragments recognizing various epitopes of the CD4bs neutralize a broad range of HIV-1 subtypes A, B and C","volume":"7","author":"Strokappe","year":"2012","journal-title":"PloS One."},{"key":"10.1016\/j.clim.2023.109809_bb0485","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1084\/jem.20112655","article-title":"Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization","volume":"209","author":"McCoy","year":"2012","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2023.109809_bb0490","doi-asserted-by":"crossref","first-page":"8390","DOI":"10.1038\/s41598-017-08273-7","article-title":"Selection of nanobodies with broad neutralizing potential against primary HIV-1 strains using soluble subtype C gp140 envelope trimers","volume":"7","author":"Koch","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.clim.2023.109809_bb0495","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/antib8020038","article-title":"Super Potent Bispecific Llama VHH Antibodies Neutralize HIV via a Combination of gp41 and gp120 Epitopes","volume":"8","author":"Strokappe","year":"2019","journal-title":"Antibodies."},{"key":"10.1016\/j.clim.2023.109809_bb0500","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13075-015-0651-0","article-title":"The preclinical pharmacology of the high affinity anti-IL-6R Nanobody\u00ae ALX-0061 supports its clinical development in rheumatoid arthritis","volume":"17","author":"Van Roy","year":"2015","journal-title":"Arthrit. Res. Ther."},{"key":"10.1016\/j.clim.2023.109809_bb0505","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.canlet.2009.08.003","article-title":"Differential tumor-targeting abilities of three single-domain antibody formats","volume":"289","author":"Bell","year":"2010","journal-title":"Cancer Lett."},{"key":"10.1016\/j.clim.2023.109809_bb0510","doi-asserted-by":"crossref","DOI":"10.1186\/s12985-022-01876-1","article-title":"HIV-1 bispecific antibody iMab-N6 exhibits enhanced breadth but not potency over its parental antibodies iMab and N6","volume":"19","author":"Moshoette","year":"2022","journal-title":"Virol. J."},{"key":"10.1016\/j.clim.2023.109809_bb0515","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.cell.2016.05.024","article-title":"Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity","volume":"165","author":"Huang","year":"2016","journal-title":"Cell."},{"key":"10.1016\/j.clim.2023.109809_bb0520","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1038\/s41591-022-02023-7","article-title":"Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b\/2a, randomized trial","volume":"28","author":"Gunst","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2023.109809_bb0525","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S2666-5247(21)00239-1","article-title":"Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial","volume":"3","author":"Gruell","year":"2022","journal-title":"Lancet Microbe."},{"key":"10.1016\/j.clim.2023.109809_bb0530","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00470-21","article-title":"A New Small-Molecule Compound, Q308, Silences Latent HIV-1 Provirus by Suppressing Tat- and FACT-Mediated Transcription","volume":"65","author":"Zhou","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.clim.2023.109809_bb0535","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.celrep.2017.09.080","article-title":"In Vivo Suppression of HIV Rebound by Didehydro-Cortistatin A, a \u201cBlock-and-Lock\u201d Strategy for HIV-1 Treatment","volume":"21","author":"Kessing","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.clim.2023.109809_bb0540","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1038\/s41467-019-10366-y","article-title":"Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice","volume":"10","author":"Dash","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.clim.2023.109809_bb0545","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1038\/ncomms9447","article-title":"Activation and lysis of human CD4 cells latently infected with HIV-1","volume":"6","author":"Pegu","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.clim.2023.109809_bb0550","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00491-18","article-title":"Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs","volume":"92","author":"Brozy","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.clim.2023.109809_bb0555","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005233","article-title":"Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells","volume":"11","author":"Sloan","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.clim.2023.109809_bb0560","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.710273","article-title":"Elimination of SHIV Infected Cells by Combinations of Bispecific HIVxCD3 DART\u00ae Molecules","volume":"12","author":"Tuyishime","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2023.109809_bb0565","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1172\/JCI96764","article-title":"Tandem bispecific neutralizing antibody eliminates HIV-1 infection in humanized mice","volume":"128","author":"Wu","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2023.109809_bb0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109611","article-title":"Tandem bispecific antibody prevents pathogenic SHIVSF162P3CN infection and disease progression","volume":"36","author":"Niu","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.clim.2023.109809_bb0575","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1006\/mthe.2002.0611","article-title":"A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy","volume":"5","author":"Deeks","year":"2002","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.clim.2023.109809_bb0580","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood.V96.3.785.015k10_785_793","article-title":"Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects","volume":"96","author":"Mitsuyasu","year":"2000","journal-title":"Blood."},{"key":"10.1016\/j.clim.2023.109809_bb0585","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ymthe.2016.12.023","article-title":"Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells","volume":"25","author":"Hale","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.clim.2023.109809_bb0590","doi-asserted-by":"crossref","first-page":"6999","DOI":"10.1128\/JVI.00805-16","article-title":"HIV-1-Specific chimeric antigen receptors based on broadly neutralizing antibodies","volume":"90","author":"Ali","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.clim.2023.109809_bb0595","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009831","article-title":"CAR\/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection","volume":"18","author":"Pampusch","year":"2022","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.clim.2023.109809_bb0600","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.ymthe.2020.05.012","article-title":"HIV-Resistant and HIV-Specific CAR-Modified CD4+ T Cells Mitigate HIV Disease Progression and Confer CD4+ T Cell Help In Vivo","volume":"28","author":"Maldini","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.clim.2023.109809_bb0605","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.omtm.2022.04.007","article-title":"Pre-clinical data supporting immunotherapy for HIV using CMV-HIV-specific CAR T cells with CMV vaccine","volume":"25","author":"Guan","year":"2022","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"key":"10.1016\/j.clim.2023.109809_bb0610","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150211","article-title":"Broadly neutralizing antibody\u2013derived CAR T cells reduce viral reservoir in individuals infected with HIV-1","volume":"131","author":"Liu","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2023.109809_bb0615","doi-asserted-by":"crossref","first-page":"6685","DOI":"10.1128\/JVI.00474-15","article-title":"Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity","volume":"89","author":"Liu","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.clim.2023.109809_bb0620","doi-asserted-by":"crossref","first-page":"eaav5685","DOI":"10.1126\/scitranslmed.aav5685","article-title":"Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model","volume":"11","author":"Anthony-Gonda","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.clim.2023.109809_bb0625","doi-asserted-by":"crossref","first-page":"693","DOI":"10.4049\/immunohorizons.2200073","article-title":"HIV-Specific CAR T Cells with CD28 or 4-1BB Signaling Domains Are Phenotypically and Functionally Distinct and Effective at Suppressing HIV and Simian Immunodeficiency Virus","volume":"6","author":"Cartwright","year":"2022","journal-title":"ImmunoHorizons."},{"key":"10.1016\/j.clim.2023.109809_bb0630","doi-asserted-by":"crossref","first-page":"1032537","DOI":"10.3389\/fimmu.2022.1032537","article-title":"Development of an anti-CAR antibody response in SIV-infected rhesus macaques treated with CD4-MBL CAR\/CXCR5 T cells","volume":"13","author":"Davey","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2023.109809_bb0635","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/978-1-0716-1944-5_12","article-title":"Production and Characterization of SIV-Specific CAR\/CXCR5 T Cells","volume":"2421","author":"Pampusch","year":"2022","journal-title":"Methods Mol. Biol. Clifton NJ."},{"key":"10.1016\/j.clim.2023.109809_bb0640","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nature19317","article-title":"Follicular CXCR5-expressing CD8+ T cells curtail chronic viral infection","volume":"537","author":"He","year":"2016","journal-title":"Nature."},{"key":"10.1016\/j.clim.2023.109809_bb0645","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ni.3543","article-title":"CXCR5(+) follicular cytotoxic T cells control viral infection in B cell follicles","volume":"17","author":"Leong","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.clim.2023.109809_bb0650","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.622343","article-title":"The PhenoCure Study Group, Cytotoxic CD8+ T Cells Expressing CXCR5 Are Detectable in HIV-1 Elite Controllers After Prolonged In Vitro Peptide Stimulation","volume":"11","author":"Adams","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2023.109809_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103794","article-title":"Implications of the accumulation of CXCR5+ NK cells in lymph nodes of HIV-1 infected patients","volume":"75","author":"Guo","year":"2022","journal-title":"EBioMedicine."},{"key":"10.1016\/j.clim.2023.109809_bb0660","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.155601","article-title":"Lymph node CXCR5+ NK cells associate with control of chronic SHIV infection","volume":"7","author":"Rahman","year":"2022","journal-title":"JCI Insight."},{"key":"10.1016\/j.clim.2023.109809_bb0665","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s11060-019-03311-y","article-title":"Shortened ex vivo manufacturing time of EGFRvIII-specific chimeric antigen receptor (CAR) T cells reduces immune exhaustion and enhances antiglioma therapeutic function","volume":"145","author":"Caruso","year":"2019","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.clim.2023.109809_bb0670","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/mt.2015.102","article-title":"HIV-specific Immunity Derived From Chimeric Antigen Receptor-engineered Stem Cells","volume":"23","author":"Zhen","year":"2015","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.clim.2023.109809_bb0675","series-title":"Allogeneic Gene-Edited HIV-Specific CAR-T Cells Secreting PD-1 Blocking scFv Enhance Anti-HIV Activity in Vitro","author":"Pan","year":"2022"},{"key":"10.1016\/j.clim.2023.109809_bb0680","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.684016","article-title":"HIV-1-Specific CAR-T Cells With Cell-Intrinsic PD-1 Checkpoint Blockade Enhance Anti-HIV Efficacy in vivo","volume":"12","author":"Jiang","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.clim.2023.109809_bb0685","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jcyt.2014.12.002","article-title":"Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2","volume":"17","author":"Gargett","year":"2015","journal-title":"Cytotherapy."},{"key":"10.1016\/j.clim.2023.109809_bb0690","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2023.109809_bb0695","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jcyt.2020.01.015","article-title":"The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma","volume":"22","author":"Cao","year":"2020","journal-title":"Cytotherapy."},{"key":"10.1016\/j.clim.2023.109809_bb0700","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.clim.2023.109809_bb0705","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","article-title":"T cells expressing chimeric antigen receptors can cause anaphylaxis in humans","volume":"1","author":"Maus","year":"2013","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.clim.2023.109809_bb0710","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2020-142612","article-title":"Macrophage Activation Syndrome-like Manifestations (MAS-L) Following BCMA-Directed CAR T-Cells in Multiple Myeloma","volume":"136","author":"Kennedy","year":"2020","journal-title":"Blood."},{"key":"10.1016\/j.clim.2023.109809_bb0715","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.bbmt.2019.11.027","article-title":"Coagulation Disorders after Chimeric Antigen Receptor T Cell Therapy: Analysis of 100 Patients with Relapsed and Refractory Hematologic Malignancies","volume":"26","author":"Wang","year":"2020","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"10.1016\/j.clim.2023.109809_bb0720","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ajh.26113","article-title":"Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies","volume":"96","author":"Nagle","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.clim.2023.109809_bb0725","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","article-title":"Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors","volume":"167","author":"Roybal","year":"2016","journal-title":"Cell."},{"key":"10.1016\/j.clim.2023.109809_bb0730","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell."},{"key":"10.1016\/j.clim.2023.109809_bb0735","doi-asserted-by":"crossref","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1\u2013 and CTLA-4\u2013Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.clim.2023.109809_bb0740","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12967-023-04041-6","article-title":"Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility","volume":"21","author":"Celichowski","year":"2023","journal-title":"J. Transl. Med."},{"issue":"168","key":"10.1016\/j.clim.2023.109809_bb0745","first-page":"2240","article-title":"Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo","volume":"1950","author":"Schuurhuis","year":"2002","journal-title":"J. Immunol. Baltim. Md"},{"key":"10.1016\/j.clim.2023.109809_bb0750","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201214","article-title":"Immunotherapy during the acute SHIV infection of macaques confers long-term suppression of viremia","volume":"218","author":"Nishimura","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2023.109809_bb0755","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41591-019-0747-1","article-title":"Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity","volume":"26","author":"Niessl","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2023.109809_bb0760","doi-asserted-by":"crossref","first-page":"eaau0528","DOI":"10.1126\/scitranslmed.aau0528","article-title":"Augmentation of HIV-specific T cell function by immediate treatment of hyperacute HIV-1 infection","volume":"11","author":"Ndhlovu","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.clim.2023.109809_bb0765","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41586-018-0600-6","article-title":"Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys","volume":"563","author":"Borducchi","year":"2018","journal-title":"Nature."},{"key":"10.1016\/j.clim.2023.109809_bb0770","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1080\/19420862.2019.1633883","article-title":"Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life","volume":"11","author":"Mackness","year":"2019","journal-title":"MAbs."},{"key":"10.1016\/j.clim.2023.109809_bb0775","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nature13612","article-title":"Enhanced neonatal Fc receptor function improves protection against primate SHIV infection","volume":"514","author":"Ko","year":"2014","journal-title":"Nature."},{"key":"10.1016\/j.clim.2023.109809_bb0780","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine, N","volume":"383","author":"Polack","year":"2020","journal-title":"Engl. J. Med."},{"key":"10.1016\/j.clim.2023.109809_bb0785","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2023.109809_bb0790","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41591-021-01573-6","article-title":"A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus","volume":"27","author":"August","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2023.109809_bb0795","article-title":"Rational design and in vivo characterization of mRNA-encoded broadly neutralizing antibody combinations against HIV-1","volume":"11","author":"Narayanan","year":"2022","journal-title":"Antibod. Basel Switz."},{"key":"10.1016\/j.clim.2023.109809_bb0800","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s40001-022-00695-y","article-title":"Acute cardiac side effects after COVID-19 mRNA vaccination: a case series","volume":"27","author":"Freise","year":"2022","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.clim.2023.109809_bb0805","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S1473-3099(21)00467-9","article-title":"The association between COVID-19 vaccination and Bell\u2019s palsy","volume":"22","author":"Cirillo","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.clim.2023.109809_bb0810","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.2940","article-title":"Incidence of Cerebral Venous Thrombosis Following SARS-CoV-2 Infection vs mRNA SARS-CoV-2 Vaccination in Singapore","volume":"5","author":"Tu","year":"2022","journal-title":"JAMA Netw. Open"},{"issue":"6","key":"10.1016\/j.clim.2023.109809_bb0815","doi-asserted-by":"crossref","first-page":"e2218512","DOI":"10.1001\/jamanetworkopen.2022.18512","article-title":"Myocarditis or Pericarditis Following mRNA COVID-19 Vaccination","volume":"5","author":"Weintraub","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clim.2023.109809_bb0820","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jama.2021.21699","article-title":"Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older","volume":"327","author":"Jabagi","year":"2022","journal-title":"JAMA."},{"key":"10.1016\/j.clim.2023.109809_bb0825","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1126\/science.abj4176","article-title":"Durability of mRNA-1273 vaccine\u2013induced antibodies against SARS-CoV-2 variants","volume":"vol. 373","author":"Pegu","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.clim.2023.109809_bb0830","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2022-000302","article-title":"Vascular thrombosis after single dose Ad26.COV2.S vaccine in healthcare workers in South Africa: open label, single arm, phase 3B study (Sisonke study)","volume":"2","author":"Jacobson","year":"2023","journal-title":"BMJ Med."},{"key":"10.1016\/j.clim.2023.109809_bb0835","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.immuni.2019.02.005","article-title":"Adeno-associated virus delivery of anti-HIV monoclonal antibodies can drive long-term virologic suppression","volume":"50","author":"Martinez-Navio","year":"2019","journal-title":"Immunity."},{"key":"10.1016\/j.clim.2023.109809_bb0840","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nm.3471","article-title":"Vectored ImmunoProphylaxis Protects Humanized Mice from Mucosal HIV Transmission","volume":"20","author":"Balazs","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2023.109809_bb0845","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1016\/S2352-3018(19)30003-7","article-title":"Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial","volume":"6","author":"Priddy","year":"2019","journal-title":"Lancet HIV."},{"key":"10.1016\/j.clim.2023.109809_bb0850","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s41591-022-01762-x","article-title":"Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial","volume":"28","author":"Casazza","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2023.109809_bb0855","doi-asserted-by":"crossref","first-page":"5850","DOI":"10.1038\/s41467-020-19650-8","article-title":"Vaccine elicitation of HIV broadly neutralizing antibodies from engineered B cells","volume":"11","author":"Huang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.clim.2023.109809_bb0860","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1084\/jem.20190287","article-title":"HIV-specific humoral immune responses by CRISPR\/Cas9-edited B cells","volume":"216","author":"Hartweger","year":"2019","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2023.109809_bb0865","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/s41587-022-01328-9","article-title":"In vivo engineered B cells secrete high titers of broadly neutralizing anti-HIV antibodies in mice","volume":"40","author":"Nahmad","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.clim.2023.109809_bb0870","doi-asserted-by":"crossref","first-page":"5851","DOI":"10.1038\/s41467-020-19649-1","article-title":"Engineered B cells expressing an anti-HIV antibody enable memory retention, isotype switching and clonal expansion","volume":"11","author":"Nahmad","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.clim.2023.109809_bb0875","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.omtm.2020.08.015","article-title":"Engineered Antigen-Specific T Cells Secreting Broadly Neutralizing Antibodies: Combining Innate and Adaptive Immune Response against HIV","volume":"19","author":"Powell","year":"2020","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"key":"10.1016\/j.clim.2023.109809_bb0880","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1187659","article-title":"Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1","volume":"329","author":"Wu","year":"2010","journal-title":"Science."},{"key":"10.1016\/j.clim.2023.109809_bb0885","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1126\/science.1178746","article-title":"Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target","volume":"326","author":"Walker","year":"2009","journal-title":"Science."},{"key":"10.1016\/j.clim.2023.109809_bb0890","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nature10373","article-title":"Broad neutralization coverage of HIV by multiple highly potent antibodies","volume":"477","author":"Walker","year":"2011","journal-title":"Nature."},{"key":"10.1016\/j.clim.2023.109809_bb0895","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023532","article-title":"Isolation of a Human Anti-HIV gp41 Membrane Proximal Region Neutralizing Antibody by Antigen-Specific Single B Cell Sorting","volume":"6","author":"Morris","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.clim.2023.109809_bb0900","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.immuni.2014.04.009","article-title":"Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the pre-fusion conformation of the gp41 protein on cleaved Envelope trimers","volume":"40","author":"Falkowska","year":"2014","journal-title":"Immunity."},{"key":"10.1016\/j.clim.2023.109809_bb0905","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1128\/JVI.02378-14","article-title":"Polyreactivity and autoreactivity among HIV-1 antibodies","volume":"89","author":"Liu","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.clim.2023.109809_bb0910","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1126\/science.1111781","article-title":"Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies","volume":"308","author":"Haynes","year":"2005","journal-title":"Science."},{"key":"10.1016\/j.clim.2023.109809_bb0915","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/f1f8c791-61e9-45c6-a455-92c6dadf9f06","article-title":"The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies","volume":"9","author":"Sok","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.clim.2023.109809_bb0920","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.chom.2014.08.006","article-title":"Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies","volume":"16","author":"Kepler","year":"2014","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.clim.2023.109809_bb0925","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1398-9995.2009.02280.x","article-title":"Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions","volume":"65","author":"Vultaggio","year":"2010","journal-title":"Allergy."},{"key":"10.1016\/j.clim.2023.109809_bb0930","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1007\/s10875-012-9705-0","article-title":"IgG4 production against adalimumab during long term treatment of RA patients","volume":"32","author":"van Schouwenburg","year":"2012","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2023.109809_bb0935","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1208\/s12248-015-9857-y","article-title":"Evaluating and reporting the immunogenicity impacts for biological products--a clinical pharmacology perspective","volume":"18","author":"Wang","year":"2016","journal-title":"AAPS J."},{"key":"10.1016\/j.clim.2023.109809_bb0940","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cell.2013.03.018","article-title":"Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization","volume":"153","author":"Klein","year":"2013","journal-title":"Cell."},{"key":"10.1016\/j.clim.2023.109809_bb0945","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.ymthe.2019.01.004","article-title":"Anti-drug antibody responses impair prophylaxis mediated by AAV-delivered HIV-1 broadly neutralizing antibodies","volume":"27","author":"Gardner","year":"2019","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.clim.2023.109809_bb0950","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/mt.2015.191","article-title":"Host Anti-antibody Responses Following Adeno-associated Virus\u2013mediated Delivery of Antibodies Against HIV and SIV in Rhesus Monkeys","volume":"24","author":"Martinez-Navio","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.clim.2023.109809_bb0955","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.749891","article-title":"Anti-Drug Antibodies in Pigtailed Macaques Receiving HIV Broadly Neutralising Antibody PGT121","volume":"12","author":"Lee","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2023.109809_bb0960","doi-asserted-by":"crossref","first-page":"3072586","DOI":"10.1155\/2016\/3072586","article-title":"Understanding the supersensitive anti-drug antibody assay: unexpected high anti-drug antibody incidence and its clinical relevance","volume":"2016","author":"Song","year":"2016","journal-title":"J Immunol Res"},{"key":"10.1016\/j.clim.2023.109809_bb0965","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.cell.2018.03.061","article-title":"Identification of Near-Pan-neutralizing Antibodies against HIV-1 by Deconvolution of Plasma Humoral Responses","volume":"173","author":"Sajadi","year":"2018","journal-title":"Cell."},{"key":"10.1016\/j.clim.2023.109809_bb0970","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.immuni.2016.10.027","article-title":"Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth","volume":"45","author":"Huang","year":"2016","journal-title":"Immunity."},{"key":"10.1016\/j.clim.2023.109809_bb0975","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2020.01.010","article-title":"Restriction of HIV-1 escape by a highly broad and potent neutralizing antibody","volume":"180","author":"Schommers","year":"2020","journal-title":"Cell."},{"key":"10.1016\/j.clim.2023.109809_bb0980","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1126\/science.1207227","article-title":"Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding","volume":"333","author":"Scheid","year":"2011","journal-title":"Science."},{"key":"10.1016\/j.clim.2023.109809_bb0985","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.cell.2016.02.022","article-title":"Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody","volume":"165","author":"Bonsignori","year":"2016","journal-title":"Cell."},{"key":"10.1016\/j.clim.2023.109809_bb0990","doi-asserted-by":"crossref","first-page":"12669","DOI":"10.1128\/JVI.02213-14","article-title":"Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo","volume":"88","author":"Rudicell","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.clim.2023.109809_bb0995","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.cell.2015.05.007","article-title":"Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors","volume":"161","author":"Zhou","year":"2015","journal-title":"Cell."},{"key":"10.1016\/j.clim.2023.109809_bb1000","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1126\/science.1207532","article-title":"Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing","volume":"333","author":"Wu","year":"2011","journal-title":"Science."},{"key":"10.1016\/j.clim.2023.109809_bb1005","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature12053","article-title":"Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus","volume":"496","author":"Liao","year":"2013","journal-title":"Nature."},{"key":"10.1016\/j.clim.2023.109809_bb1010","doi-asserted-by":"crossref","first-page":"5863","DOI":"10.1128\/JVI.77.10.5863-5876.2003","article-title":"Molecular Features of the Broadly Neutralizing Immunoglobulin G1 b12 Required for Recognition of Human Immunodeficiency Virus Type 1 gp120","volume":"77","author":"Zwick","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.clim.2023.109809_bb1015","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1126\/science.1233989","article-title":"Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization","volume":"340","author":"Georgiev","year":"2013","journal-title":"Science."},{"key":"10.1016\/j.clim.2023.109809_bb1020","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/nsmb.3291","article-title":"Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site","volume":"23","author":"Gristick","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.clim.2023.109809_bb1025","article-title":"A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals","volume":"88","author":"Dr","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2023.109809_bb1030","doi-asserted-by":"crossref","first-page":"11231","DOI":"10.1128\/JVI.01543-12","article-title":"HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins","volume":"86","author":"Li","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.clim.2023.109809_bb1035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005238","article-title":"A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo","volume":"11","author":"Freund","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.clim.2023.109809_bb1040","doi-asserted-by":"crossref","first-page":"E3268","DOI":"10.1073\/pnas.1217207109","article-title":"Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies","volume":"109","author":"Mouquet","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2023.109809_bb1045","doi-asserted-by":"crossref","first-page":"eaal2144","DOI":"10.1126\/scitranslmed.aal2144","article-title":"Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller","volume":"9","author":"Freund","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.clim.2023.109809_bb1050","doi-asserted-by":"crossref","first-page":"eaai7514","DOI":"10.1126\/scitranslmed.aai7514","article-title":"Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies","volume":"9","author":"Bonsignori","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.clim.2023.109809_bb1055","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.immuni.2016.06.026","article-title":"A prominent site of antibody vulnerability on HIV envelope incorporates a motif associated with CCR5 binding and its camouflaging glycans","volume":"45","author":"Sok","year":"2016","journal-title":"Immunity."},{"key":"10.1016\/j.clim.2023.109809_bb1060","doi-asserted-by":"crossref","first-page":"eaai7521","DOI":"10.1126\/scitranslmed.aai7521","article-title":"Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide","volume":"9","author":"Alam","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.clim.2023.109809_bb1065","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.immuni.2016.04.016","article-title":"Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch","volume":"44","author":"MacLeod","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2023.109809_bb1070","doi-asserted-by":"crossref","first-page":"eabb1328","DOI":"10.1126\/sciadv.abb1328","article-title":"A VH1-69 antibody lineage from an infected Chinese donor potently neutralizes HIV-1 by targeting the V3 glycan supersite","volume":"6","author":"Kumar","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.clim.2023.109809_bb1075","doi-asserted-by":"crossref","first-page":"10574","DOI":"10.1128\/JVI.01012-16","article-title":"Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding","volume":"90","author":"Longo","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.clim.2023.109809_bb1080","doi-asserted-by":"crossref","first-page":"10700","DOI":"10.1128\/JVI.01111-10","article-title":"Very Few Substitutions in a Germ Line Antibody Are Required To Initiate Significant Domain Exchange","volume":"84","author":"Huber","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.clim.2023.109809_bb1085","doi-asserted-by":"crossref","first-page":"17624","DOI":"10.1073\/pnas.1415789111","article-title":"Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex","volume":"111","author":"Sok","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2023.109809_bb1090","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1128\/JVI.01791-15","article-title":"New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency","volume":"90","author":"Doria-Rose","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.clim.2023.109809_bb1095","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature13036","article-title":"Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies","volume":"509","author":"Doria-Rose","year":"2014","journal-title":"Nature."},{"key":"10.1016\/j.clim.2023.109809_bb1100","doi-asserted-by":"crossref","first-page":"9998","DOI":"10.1128\/JVI.05045-11","article-title":"Analysis of a clonal lineage of HIV-1 envelope V2\/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors","volume":"85","author":"Bonsignori","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.clim.2023.109809_bb1105","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.immuni.2017.11.002","article-title":"HIV envelope glycoform heterogeneity and localized diversity govern the initiation and maturation of a V2 Apex broadly neutralizing antibody lineage","volume":"47","author":"Landais","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2023.109809_bb1110","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.immuni.2017.04.011","article-title":"Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop","volume":"46","author":"Cale","year":"2017","journal-title":"Immunity."},{"key":"10.1016\/j.clim.2023.109809_bb1115","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nature11544","article-title":"Broad and potent neutralization of HIV-1 by a gp41-specific human antibody","volume":"491","author":"Huang","year":"2012","journal-title":"Nature."},{"key":"10.1016\/j.clim.2023.109809_bb1120","doi-asserted-by":"crossref","first-page":"eaal2200","DOI":"10.1126\/sciimmunol.aal2200","article-title":"Potent and broad HIV-neutralizing antibodies in memory B cells and plasma","volume":"2","author":"Williams","year":"2017","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.clim.2023.109809_bb1125","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.chom.2019.09.016","article-title":"Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01","volume":"26","author":"Pinto","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.clim.2023.109809_bb1130","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1128\/JVI.78.6.3155-3161.2004","article-title":"The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5","volume":"78","author":"Zwick","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.clim.2023.109809_bb1135","doi-asserted-by":"crossref","first-page":"11401","DOI":"10.1128\/JVI.05312-11","article-title":"Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies","volume":"85","author":"Zhu","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.clim.2023.109809_bb1140","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/nature13601","article-title":"Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface","volume":"515","author":"Huang","year":"2014","journal-title":"Nature."},{"key":"10.1016\/j.clim.2023.109809_bb1145","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1126\/science.aae0474","article-title":"Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody","volume":"352","author":"Kong","year":"2016","journal-title":"Science."},{"key":"10.1016\/j.clim.2023.109809_bb1150","doi-asserted-by":"crossref","first-page":"16199","DOI":"10.1038\/nmicrobiol.2016.199","article-title":"An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability","volume":"2","author":"van Gils","year":"2016","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.clim.2023.109809_bb1155","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.immuni.2018.02.013","article-title":"A Neutralizing Antibody Recognizing Primarily N-linked Glycan Targets the Silent Face of the HIV Envelope","volume":"48","author":"Zhou","year":"2018","journal-title":"Immunity."},{"key":"10.1016\/j.clim.2023.109809_bb1160","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.immuni.2019.04.014","article-title":"Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope","volume":"50","author":"Schoofs","year":"2019","journal-title":"Immunity."},{"key":"10.1016\/j.clim.2023.109809_bb1165","author":"CATNAP"},{"key":"10.1016\/j.clim.2023.109809_bb1170","author":"Neutralizing Antibody Resources"},{"key":"10.1016\/j.clim.2023.109809_bb1175","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.chom.2018.12.001","article-title":"HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design","volume":"25","author":"Bricault","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.clim.2023.109809_bb1180","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1007\/s00705-018-4011-7","article-title":"Evaluation of susceptibility of HIV-1 CRF01_AE variants to neutralization by a panel of broadly neutralizing antibodies","volume":"163","author":"Wang","year":"2018","journal-title":"Arch. Virol."},{"key":"10.1016\/j.clim.2023.109809_bb1195","first-page":"8","article-title":"Safety and single-dose pharmacokinetics of VRC07-523LS administered via different routes and doses","volume":"24","author":"Walsh","year":"2021","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.clim.2023.109809_bb1205","series-title":"VH3810109 (N6LS) Reduces Viremia Across a Range of Doses in ART-Naive Adults Living With HIV: Proof of Concept Achieved in the Phase IIa BANNER (207959, NCT04871113) Study","author":"Leone","year":"2023"}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661623005727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661623005727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:12:06Z","timestamp":1761495126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661623005727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":236,"alternative-id":["S1521661623005727"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2023.109809","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Broadly neutralizing antibodies targeting HIV: Progress and challenges","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2023.109809","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109809"}}